Table 1 Patient demographic and clinical characteristics
Number of patients (n = 48) | (%) | |
|---|---|---|
Age | ||
Median | 76 | |
Min-Max | 70–86 | |
Sex | ||
Male | 24 | 50.0 |
Female | 24 | 50.0 |
Performance status (WHO) | ||
0 | 11 | 22.9 |
1 | 33 | 68.8 |
2 | 4 | 8.3 |
Previous Treatment | ||
Surgery | 36 | 75.0 |
Adjuvant chemotherapy | 9 | 18.8 |
Adjuvant radiotherapy | 4 | 8.3 |
Disease Sites | ||
Lymph nodes | 15 | 31.3 |
Liver | 36 | 75.0 |
Lung | 17 | 35.4 |
Other | 11 | 23 |
Number of Metastatic Sites | ||
1 | 22 | 45.8 |
2 | 14 | 29.2 |
3 | 10 | 20.8 |
4 | 1 | 2.1 |
CGA (n = 48) | ||
Fit | 25 | 52.0 |
Vulnerable | 23 | 48.0 |
GDS (n = 30) | ||
≤5 | 22 | 73.3 |
>5 | 8 | 26.7 |
Median | 4 | |
Range | 1–12 | |
MMSE (n = 32) | ||
<24 | 4 | 12.5 |
≥24 | 28 | 27.5 |
Median | 27 | |
Range | 3–30 | |
IADL (n = 37) | ||
<7 | 10 | 73.3 |
7–8 | 27 | 26.7 |
Median | 8.0 | |
Range | 3–8 | |
Charlson Comorbidity Index | ||
Median | 1 | |
Range | 0–2 | |
Body Mass Index | ||
Median | 27.75 | |
Range | 18.0–35.0 | |
Haemoglobin (gr/dL) | ||
Median | 11.8 | |
Range | 9.7–16.4 | |
Albumin (gr/dL) | ||
Median | 3.9 | |
Range | 2.6–4.8 | |
Medications | ||
Median | 1 | |
Range | 0–4 |